A	0	0
large	2	6
outbreak	8	15
of	17	18
Salmonella	20	29
Paratyphi	31	39
A	41	41
infection	43	51
among	53	57
israeli	59	65
travelers	67	75
to	77	78
Nepal	80	84
.	85	85

In	87	88
Asia	90	93
,	94	94
Salmonella	96	105
Paratyphi	107	115
A	117	117
is	119	120
an	122	123
emerging	125	132
infection	134	142
,	143	143
and	145	147
travelers	149	157
are	159	161
increasingly	163	174
at	176	177
risk	179	182
.	183	183

During	185	190
October	192	198
2009	200	203
-	204	204
November	205	212
2009	214	217
,	218	218
an	220	221
outbreak	223	230
in	232	233
S	235	235
.	236	236
Paratyphi	238	246
A	248	248
infection	250	258
was	260	262
noted	264	268
in	270	271
Israeli	273	279
travelers	281	289
returning	291	299
from	301	304
Nepal	306	310
.	311	311

An	313	314
outbreak	316	323
investigation	325	337
included	339	346
a	348	348
standardized	350	361
exposure	363	370
questionnaire	372	384
admitted	386	393
to	395	396
all	398	400
patients	402	409
and	411	413
medical	415	421
chart	423	427
abstraction	429	439
.	440	440

Isolates	442	449
were	451	454
tested	456	461
for	463	465
antimicrobial	467	479
susceptibility	481	494
and	496	498
pulsed	500	505
-	506	506
field	507	511
gel	513	515
electrophoresis	517	531
(	533	533
PFGE	534	537
)	538	538
.	539	539

During	541	546
1	548	548
October	550	556
2009	558	561
-	562	562
30	563	564
November	566	573
2009	575	578
,	579	579
37	581	582
Israeli	584	590
travelers	592	600
returning	602	610
from	612	615
Nepal	617	621
were	623	626
diagnosed	628	636
with	638	641
S	643	643
.	644	644
Paratyphi	646	654
A	656	656
bacteremia	658	667
.	668	668

All	670	672
37	674	675
case	677	680
isolates	682	689
had	691	693
an	695	696
identical	698	706
pattern	708	714
on	716	717
PFGE	719	722
,	723	723
and	725	727
all	729	731
were	733	736
nalidixic	738	746
acid	748	751
resistant	753	761
.	762	762

Only	764	767
1	769	769
food	771	774
venue	776	780
was	782	784
frequented	786	795
by	797	798
all	800	802
the	804	806
outbreak	808	815
cases	817	821
,	822	822
with	824	827
the	829	831
largest	833	839
number	841	846
of	848	849
exposures	851	859
occurring	861	869
around	871	876
the	878	880
Jewish	882	887
New	889	891
Year	893	896
.	897	897

All	899	901
patients	903	910
recovered	912	920
without	922	928
complications	930	942
.	943	943

Time	945	948
to	950	951
defervescence	953	965
in	967	968
17	970	971
patients	973	980
treated	982	988
with	990	993
ceftriaxone	995	1005
and	1007	1009
azithromycin	1011	1022
combination	1024	1034
was	1036	1038
3	1040	1040
.	1041	1041
2	1042	1042
days	1044	1047
(	1049	1049
±	1050	1050
1	1052	1052
.	1053	1053
7	1054	1054
)	1055	1055
,	1056	1056
whereas	1058	1064
in	1066	1067
13	1069	1070
cases	1072	1076
treated	1078	1084
with	1086	1089
ceftriaxone	1091	1101
monotherapy	1103	1113
,	1114	1114
the	1116	1118
time	1120	1123
to	1125	1126
defervescence	1128	1140
was	1142	1144
6	1146	1146
.	1147	1147
6	1148	1148
days	1150	1153
(	1155	1155
±	1156	1156
1	1158	1158
.	1159	1159
8	1160	1160
;	1161	1161
P	1163	1163
<	1165	1165
.	1167	1167
001	1168	1170
)	1171	1171
.	1172	1172

A	1174	1174
point	1176	1180
-	1181	1181
source	1182	1187
,	1188	1188
"	1190	1190
Paratyphoid	1191	1201
Mary	1203	1206
"	1207	1207
-	1208	1208
like	1209	1212
outbreak	1214	1221
was	1223	1225
identified	1227	1236
among	1238	1242
Israeli	1244	1250
travelers	1252	1260
to	1262	1263
Nepal	1265	1269
.	1270	1270

Combination	1272	1282
Ceftriaxone	1284	1294
-	1295	1295
Azithromycin	1296	1307
therapy	1309	1315
may	1317	1319
provide	1321	1327
a	1329	1329
therapeutic	1331	1341
advantage	1343	1351
over	1353	1356
monotherapy	1358	1368
,	1369	1369
and	1371	1373
merits	1375	1380
further	1382	1388
clinical	1390	1397
trials	1399	1404
.	1405	1405
